Melanoma Clinical Trial Landscape
Data updated: May 20, 2026
1,641 clinical trials tracked since 2008
Melanoma is a type of skin cancer that develops from melanocytes, the cells that produce melanin. While it can occur anywhere on the body, it most often affects skin that has been exposed to the sun. The clinical trial landscape for melanoma is robust, with 1,633 trials registered since 2008, and 515 currently active. Activity is heavily concentrated in early-phase trials, with 256 active Phase 1 and 312 active Phase 2 trials, compared to 59 active Phase 3 and 8 active Phase 4 trials. Several industry sponsors are actively involved in melanoma research. Merck, Bristol-Myers Squibb, Novartis, and Regeneron are each sponsoring 6 or 7 active trials, and Iovance Biotherapeutics, Inc. is also sponsoring 6 active trials. The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in this indication.
519 active
/
1641 total (since 2008)
258
Phase 1 Active
863 total
312
Phase 2 Active
937 total
61
Phase 3 Active
138 total
9
Phase 4 Active
21 total
Top Industry Sponsors
Sorted by active Active Done Failed
Merck 7 18 3
Bristol-Myers Squibb 6 39 11
Novartis 6 14 8
Regeneron 6 3 2
Iovance Biotherapeutics, Inc. 5 1 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT02339571 ACTIVE NOT RECRUITING
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI) n=600
NCT02821013 RECRUITING
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Canadian Cancer Trials Group n=614
NCT06697301 RECRUITING
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics n=740
NCT06246916 RECRUITING
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals n=560
+ 133 more Phase 3 trials — see full database below
Melanoma — Trials Started by Year (last 10 years)
2016 94
2017 84
2018 102
2019 87
2020 87
2021 111
2022 103
2023 87
2024 74
2025 96
2026 51
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Merck 28
Bristol-Myers Squibb 56
Novartis 28
Regeneron 11
Iovance Biotherapeutics, Inc. 7
Roche 45
Pfizer 26
Biocad 5
IDEAYA Biosciences 4
Philogen S.p.A. 8
Active Trials by Phase
Phase 1 258
Phase 2 312
Phase 3 61
Phase 4 9
Enrollment Size Distribution
1-50 945
51-200 427
201-500 115
501-1k 49
1k+ 18
All Industry Sponsors
Sorted by active Active Done Failed
Merck 7 18 3
Bristol-Myers Squibb 6 39 11
Novartis 6 14 8
Regeneron 6 3 2
Iovance Biotherapeutics, Inc. 5 1 1
Roche 4 36 5
Pfizer 4 8 14
Biocad 4 1 0
IDEAYA Biosciences 4 0 0
Philogen S.p.A. 3 4 1
Innovent Biologics (Suzhou) Co. Ltd. 3 0 2
Replimune, Inc. 3 0 0
Binhui Biopharmaceutical Co., Ltd. 3 0 0
AstraZeneca 2 5 0
Immunocore Ltd 2 3 2
NCT02339571 ACTIVE NOT RECRUITING
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI) n=600
NCT02821013 RECRUITING
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Canadian Cancer Trials Group n=614
NCT06697301 RECRUITING
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics n=740
NCT06246916 RECRUITING
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals n=560
NCT01274338 ACTIVE NOT RECRUITING
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI) n=1,673
NCT02506153 ACTIVE NOT RECRUITING
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI) n=1,301
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT05522660 RECRUITING
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation n=180
NCT07552597 NOT YET RECRUITING
Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
Vastra Gotaland Region n=254
NCT06624644 RECRUITING
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc. n=135
NCT05352672 ACTIVE NOT RECRUITING
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals n=1,546
NCT06743126 RECRUITING
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Immatics US, Inc. n=360
NCT04099251 ACTIVE NOT RECRUITING
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Bristol-Myers Squibb n=790
NCT04657991 ACTIVE NOT RECRUITING
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer n=257
NCT05727904 RECRUITING
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc. n=670
NCT06581406 RECRUITING
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc. n=280
NCT06264180 RECRUITING
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Replimune, Inc. n=400
NCT06488482 RECRUITING
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Uppsala University n=1,792
NCT02362594 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Merck Sharp & Dohme LLC n=1,019
NCT06246149 RECRUITING
Adjuvant Tebentafusp in High Risk Ocular Melanoma
European Organisation for Research and Treatment of Cancer - EORTC n=290
NCT06007690 RECRUITING
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Aura Biosciences n=100
NCT06346067 ACTIVE NOT RECRUITING
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc. n=78
NCT05549297 RECRUITING
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd n=540
NCT06112314 RECRUITING
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Immunocore Ltd n=680
NCT02224781 ACTIVE NOT RECRUITING
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI) n=267
NCT05987332 ACTIVE NOT RECRUITING
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences n=420
NCT07221734 RECRUITING
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L. n=632
NCT06054555 ACTIVE NOT RECRUITING
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen n=633
NCT07310758 RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute n=91
NCT03567889 RECRUITING
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Philogen S.p.A. n=186
NCT06794775 RECRUITING
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Hildur Helgadottir n=128
NCT05770544 RECRUITING
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Cancer Research UK n=30
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT05770102 RECRUITING
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Cancer Research UK n=30
NCT07068074 NOT YET RECRUITING
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
Eastern Cooperative Oncology Group n=428
NCT01223248 ACTIVE NOT RECRUITING
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center n=220
NCT05933577 ACTIVE NOT RECRUITING
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Merck Sharp & Dohme LLC n=1,089
NCT04674683 ACTIVE NOT RECRUITING
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC. n=450
NCT03470922 ACTIVE NOT RECRUITING
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Bristol-Myers Squibb n=714
NCT05155254 ACTIVE NOT RECRUITING
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
IO Biotech n=407
NCT05625399 ACTIVE NOT RECRUITING
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Bristol-Myers Squibb n=579
NCT06640530 ACTIVE NOT RECRUITING
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Biocad n=392
NCT05751928 ACTIVE NOT RECRUITING
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Biocad n=411
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05608291 ACTIVE NOT RECRUITING
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals n=1,564
NCT05899465 RECRUITING
Perioperative Treatment With Tranexamic Acid in Melanoma
University of Aarhus n=1,204
NCT05732805 ACTIVE NOT RECRUITING
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Biocad n=270
NCT03553836 ACTIVE NOT RECRUITING
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Merck Sharp & Dohme LLC n=976
NCT06519266 RECRUITING
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Vastra Gotaland Region n=40
NCT06008106 RECRUITING
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc. n=165
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT04309409 ACTIVE NOT RECRUITING
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
University Hospital, Essen n=374
NCT04949113 ACTIVE NOT RECRUITING
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
The Netherlands Cancer Institute n=423
NCT05270044 ACTIVE NOT RECRUITING
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Pierre Fabre Medicament n=815
NCT05789043 RECRUITING
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute n=140
NCT07597070 NOT YET RECRUITING
Universal Immunization to Fortify Immunotherapy Efficacy and Response
University of Florida n=1,200
NCT01682083 COMPLETED
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Novartis Pharmaceuticals n=870
NCT05907122 COMPLETED
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen n=256
NCT01909453 COMPLETED
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Pfizer n=921
NCT06587451 TERMINATED
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz n=52
NCT03820986 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Merck Sharp & Dohme LLC n=674
NCT01983748 COMPLETED
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
University Hospital Erlangen n=200
NCT05002569 TERMINATED
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Bristol-Myers Squibb n=1,093
NCT04889118 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
Merck Sharp & Dohme LLC n=131
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT01546571 TERMINATED
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Polynoma LLC n=504
NCT05665595 COMPLETED
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Merck Sharp & Dohme LLC n=1,594
NCT01861938 WITHDRAWN
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
NCT02967692 TERMINATED
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Novartis Pharmaceuticals n=568
NCT04695977 TERMINATED
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals n=20
NCT02752074 COMPLETED
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Incyte Corporation n=706
NCT02908672 COMPLETED
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche n=514
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT01844505 COMPLETED
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb n=945
NCT02166788 COMPLETED
Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited n=634
NCT03551626 COMPLETED
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
Novartis Pharmaceuticals n=552
NCT02388906 COMPLETED
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Bristol-Myers Squibb n=906
NCT03635983 COMPLETED
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb n=783
NCT03172299 COMPLETED
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Centre Hospitalier Universitaire de Nice n=57
NCT02278887 COMPLETED
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
The Netherlands Cancer Institute n=168
NCT04901988 TERMINATED
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
The Christie NHS Foundation Trust n=8
NCT05297565 COMPLETED
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
Bristol-Myers Squibb n=14
NCT01748448 COMPLETED
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Universitaire Ziekenhuizen KU Leuven n=436
NCT02993315 COMPLETED
Melanoma Patients Immunized with Natural DenDritic Cells
Radboud University Medical Center n=148
NCT03430297 COMPLETED
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd. n=256
NCT03233828 TERMINATED
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
Carman Giacomantonio n=1
NCT01785316 COMPLETED
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
Vastra Gotaland Region n=93
NCT02678572 COMPLETED
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Delcath Systems Inc. n=102
NCT04410445 TERMINATED
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Nektar Therapeutics n=765
NCT04277663 TERMINATED
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Innovent Biologics (Suzhou) Co. Ltd. n=136
NCT03928275 WITHDRAWN
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
Carman Giacomantonio
NCT03294330 COMPLETED
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
Milton S. Hershey Medical Center n=35
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT01720407 COMPLETED
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Nantes University Hospital n=259
NCT02263508 TERMINATED
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Amgen n=713
NCT03445533 TERMINATED
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc. n=481
NCT03273153 TERMINATED
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Hoffmann-La Roche n=446
NCT02843386 COMPLETED
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Institut Curie n=302
NCT01721772 COMPLETED
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Bristol-Myers Squibb n=418
NCT02714218 COMPLETED
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Bristol-Myers Squibb n=387
NCT01689519 COMPLETED
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Hoffmann-La Roche n=495
NCT01721746 COMPLETED
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb n=405
NCT02288897 TERMINATED
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Biopharmaceuticals, Inc. n=20
NCT03068455 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
Bristol-Myers Squibb n=1,844
NCT03329846 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb n=20
NCT02599402 COMPLETED
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Bristol-Myers Squibb n=533
NCT01763164 COMPLETED
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer n=402
NCT00796445 TERMINATED
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GlaxoSmithKline n=1,351
NCT01597908 COMPLETED
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Novartis Pharmaceuticals n=704
NCT01584648 COMPLETED
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis Pharmaceuticals n=423
NCT02905266 COMPLETED
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
Bristol-Myers Squibb n=106
NCT01280565 TERMINATED
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
AB Science n=134
NCT01826864 WITHDRAWN
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
NCT01866319 COMPLETED
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Merck Sharp & Dohme LLC n=834
NCT02545075 COMPLETED
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Bristol-Myers Squibb n=182
NCT00636168 COMPLETED
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Bristol-Myers Squibb n=1,211
NCT00864253 COMPLETED
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Celgene n=529
NCT01515189 COMPLETED
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Bristol-Myers Squibb n=831
NCT01667419 COMPLETED
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
Hoffmann-La Roche n=498
NCT01875653 TERMINATED
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc. n=4
NCT00540969 TERMINATED
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
Alliance for Clinical Trials in Oncology n=3
NCT01006252 TERMINATED
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
Eli Lilly and Company n=336
NCT01245062 COMPLETED
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline n=322
NCT01264874 TERMINATED
MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients
European Institute of Oncology n=150
NCT01307397 COMPLETED
A Study of Vemurafenib in Participants With Metastatic Melanoma
Hoffmann-La Roche n=3,219
NCT01974752 COMPLETED
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
AstraZeneca n=152
NCT02427893 WITHDRAWN
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01006980 COMPLETED
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche n=675
NCT00769704 COMPLETED
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited n=437
NCT01368276 COMPLETED
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited n=31
NCT00671918 COMPLETED
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Navidea Biopharmaceuticals n=186
NCT01106040 COMPLETED
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Navidea Biopharmaceuticals n=163
NCT01013623 TERMINATED
Stage IV Surgery Versus Best Medical Therapy
Saint John's Cancer Institute n=12
NCT05896839 RECRUITING
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
NCT02465060 ACTIVE NOT RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
NCT05111574 RECRUITING
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
National Cancer Institute (NCI)
NCT05136196 RECRUITING
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
NCT04708418 ACTIVE NOT RECRUITING
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
NCT01989585 ACTIVE NOT RECRUITING
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
NCT03420508 ACTIVE NOT RECRUITING
Treating Patients With Melanoma and ALK Alterations With Ensartinib
Memorial Sloan Kettering Cancer Center
NCT02196181 ACTIVE NOT RECRUITING
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
National Cancer Institute (NCI)
NCT06623461 RECRUITING
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Canadian Cancer Trials Group
NCT07287917 RECRUITING
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
NCT07310784 RECRUITING
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
NCT04464759 RECRUITING
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Ravi Amaravadi, MD
NCT05661955 ACTIVE NOT RECRUITING
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeiGene
NCT06594991 RECRUITING
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT07576725 NOT YET RECRUITING
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT02621021 RECRUITING
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Cancer Institute (NCI)
NCT05155033 RECRUITING
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Cancer Institute (NCI)
NCT06767306 RECRUITING
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Melanoma Institute Australia
NCT04728633 ACTIVE NOT RECRUITING
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
NCT04083599 ACTIVE NOT RECRUITING
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT02106598 ACTIVE NOT RECRUITING
Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
Memorial Sloan Kettering Cancer Center
NCT03122522 ACTIVE NOT RECRUITING
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Memorial Sloan Kettering Cancer Center
NCT04462406 ACTIVE NOT RECRUITING
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT06984328 ACTIVE NOT RECRUITING
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
NCT04284774 ACTIVE NOT RECRUITING
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT02332668 RECRUITING
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
NCT04851119 RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT07281924 RECRUITING
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
NCT05546827 RECRUITING
Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
M.D. Anderson Cancer Center
NCT07565285 NOT YET RECRUITING
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
Primmune Therapeutics, Inc.
NCT03698019 ACTIVE NOT RECRUITING
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
National Cancer Institute (NCI)
NCT06060613 RECRUITING
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Obsidian Therapeutics, Inc.
NCT02581930 ACTIVE NOT RECRUITING
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
NCT06305247 ACTIVE NOT RECRUITING
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT01708941 ACTIVE NOT RECRUITING
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00937937 ACTIVE NOT RECRUITING
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
NCT01134614 ACTIVE NOT RECRUITING
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06413680 RECRUITING
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT05764395 ACTIVE NOT RECRUITING
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
NCT04114136 RECRUITING
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT01416831 ACTIVE NOT RECRUITING
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Providence Health & Services
NCT04207086 ACTIVE NOT RECRUITING
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
Melanoma Institute Australia
NCT07115043 RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07527325 NOT YET RECRUITING
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
NCT03149029 ACTIVE NOT RECRUITING
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07288203 ACTIVE NOT RECRUITING
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics, Inc.
NCT02713269 ACTIVE NOT RECRUITING
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT06708663 RECRUITING
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT05026983 RECRUITING
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
NCT07223424 RECRUITING
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT03175432 ACTIVE NOT RECRUITING
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT07288112 RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Diakonos Oncology Corporation
NCT04895709 RECRUITING
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05913388 RECRUITING
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
NCT01587352 ACTIVE NOT RECRUITING
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
NCT05423262 RECRUITING
A Study of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT01979523 ACTIVE NOT RECRUITING
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT02775851 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02656706 ACTIVE NOT RECRUITING
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Brown University
NCT06961006 RECRUITING
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Merck Sharp & Dohme LLC
NCT06101134 ACTIVE NOT RECRUITING
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
NCT04305054 ACTIVE NOT RECRUITING
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Merck Sharp & Dohme LLC
NCT06099782 ACTIVE NOT RECRUITING
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Merck Sharp & Dohme LLC
NCT07517653 NOT YET RECRUITING
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Shanghai Zhongshan Hospital
NCT05289193 ACTIVE NOT RECRUITING
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT05170334 ACTIVE NOT RECRUITING
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07511036 NOT YET RECRUITING
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
NCT02830724 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT04557956 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
NCT06295159 RECRUITING
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04562129 RECRUITING
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT05524935 RECRUITING
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05267626 RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
NCT07276386 RECRUITING
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05130177 ACTIVE NOT RECRUITING
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Diwakar Davar
NCT06961357 RECRUITING
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07501104 NOT YET RECRUITING
Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma
Shanghai Zhongshan Hospital
NCT06425926 RECRUITING
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
NCT04074096 ACTIVE NOT RECRUITING
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
UNICANCER
NCT06466434 RECRUITING
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
M.D. Anderson Cancer Center
NCT06708455 NOT YET RECRUITING
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
NCT04899908 ACTIVE NOT RECRUITING
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04140500 ACTIVE NOT RECRUITING
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05907954 ACTIVE NOT RECRUITING
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
NCT02068586 ACTIVE NOT RECRUITING
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT06157099 ACTIVE NOT RECRUITING
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
OHSU Knight Cancer Institute
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT04417621 ACTIVE NOT RECRUITING
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis Pharmaceuticals
NCT05655312 RECRUITING
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Perspective Therapeutics
NCT06223659 RECRUITING
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
NCT06771544 RECRUITING
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
NCT03999749 ACTIVE NOT RECRUITING
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT07448831 RECRUITING
A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
Universitair Ziekenhuis Brussel
NCT07057596 RECRUITING
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT04940299 ACTIVE NOT RECRUITING
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT06416085 ACTIVE NOT RECRUITING
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
NCT01644591 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT07449754 RECRUITING
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
NCT07072728 RECRUITING
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
NCT04091750 ACTIVE NOT RECRUITING
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
NCT06956690 RECRUITING
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Hummingbird Bioscience
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT04771520 RECRUITING
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
NCT06070012 RECRUITING
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Diwakar Davar
NCT05081609 ACTIVE NOT RECRUITING
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT06627244 RECRUITING
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
NCT04971499 ACTIVE NOT RECRUITING
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
April Salama, M.D.
NCT06999980 RECRUITING
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Melanoma Institute Australia
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT05384496 RECRUITING
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Memorial Sloan Kettering Cancer Center
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT06237881 ACTIVE NOT RECRUITING
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT04752826 RECRUITING
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04594187 RECRUITING
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
M.D. Anderson Cancer Center
NCT05912244 ACTIVE NOT RECRUITING
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT03767348 ACTIVE NOT RECRUITING
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune, Inc.
NCT02231775 ACTIVE NOT RECRUITING
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
NCT07406724 NOT YET RECRUITING
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
NCT06190951 ACTIVE NOT RECRUITING
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
NCT07400302 RECRUITING
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
The First Hospital of Jilin University
NCT04478279 ACTIVE NOT RECRUITING
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT06548789 RECRUITING
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
M.D. Anderson Cancer Center
NCT05418972 ACTIVE NOT RECRUITING
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Melanoma Institute Australia
NCT03340129 RECRUITING
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Melanoma Institute Australia
NCT06250335 ACTIVE NOT RECRUITING
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
M.D. Anderson Cancer Center
NCT04645680 ACTIVE NOT RECRUITING
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT07376317 ACTIVE NOT RECRUITING
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
Instituto do Cancer do Estado de São Paulo
NCT03474497 ACTIVE NOT RECRUITING
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Megan Daly, MD
NCT04305145 ACTIVE NOT RECRUITING
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
NCT06365619 RECRUITING
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
University of Utah
NCT07371663 RECRUITING
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
NCT06172478 RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT03947385 RECRUITING
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
NCT07349303 RECRUITING
Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
Vastra Gotaland Region
NCT07347444 NOT YET RECRUITING
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
Fudan University
NCT06717126 ACTIVE NOT RECRUITING
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
iOnctura
NCT05529316 ACTIVE NOT RECRUITING
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Agenus Inc.
NCT03228667 ACTIVE NOT RECRUITING
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT07340619 NOT YET RECRUITING
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
UNICANCER
NCT05704647 RECRUITING
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT06214156 RECRUITING
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd
NCT07336979 RECRUITING
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
Sun Yat-sen University
NCT06848088 ENROLLING BY INVITATION
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Regeneron Pharmaceuticals
NCT05588453 RECRUITING
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT03829254 RECRUITING
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
NCT05034536 ACTIVE NOT RECRUITING
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
NCT07280832 RECRUITING
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Shanghai JMT-Bio Inc.
NCT05830058 RECRUITING
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT05428007 RECRUITING
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT00539591 ACTIVE NOT RECRUITING
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
NCT04407247 ACTIVE NOT RECRUITING
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT04079166 ACTIVE NOT RECRUITING
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Scancell Ltd
NCT04198766 ACTIVE NOT RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
NCT02910700 ACTIVE NOT RECRUITING
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT01972347 ACTIVE NOT RECRUITING
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Melanoma Institute Australia
NCT03131908 ACTIVE NOT RECRUITING
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
M.D. Anderson Cancer Center
NCT02374242 ACTIVE NOT RECRUITING
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
Melanoma Institute Australia
NCT05089370 ACTIVE NOT RECRUITING
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
University of Colorado, Denver
NCT04996823 RECRUITING
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07099430 RECRUITING
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
NCT06121180 RECRUITING
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06265285 RECRUITING
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT06194929 RECRUITING
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
University of Utah
NCT03897881 ACTIVE NOT RECRUITING
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc.
NCT07070518 RECRUITING
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT06319196 RECRUITING
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
University Health Network, Toronto
NCT06940739 RECRUITING
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Iovance Biotherapeutics, Inc.
NCT04318717 RECRUITING
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Washington University School of Medicine
NCT07136181 RECRUITING
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Novelwise Pharmaceutical Corporation
NCT05282901 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
Institut Curie
NCT06889610 RECRUITING
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Fudan University
NCT07236528 NOT YET RECRUITING
Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06784648 ACTIVE NOT RECRUITING
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
NCT02965716 ACTIVE NOT RECRUITING
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
NCT06521567 ACTIVE NOT RECRUITING
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT07155317 RECRUITING
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
NCT04074967 ACTIVE NOT RECRUITING
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT04013854 ACTIVE NOT RECRUITING
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Abramson Cancer Center at Penn Medicine
NCT04139902 ACTIVE NOT RECRUITING
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
Diwakar Davar
NCT07215182 RECRUITING
[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Barbara Malene Fischer
NCT04370587 RECRUITING
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
NCT03693014 ACTIVE NOT RECRUITING
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03915678 RECRUITING
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Institut Bergonié
NCT00722228 RECRUITING
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
NCT01898039 RECRUITING
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Hadassah Medical Organization
NCT05296564 RECRUITING
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
NCT06887088 RECRUITING
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Grupo Español Multidisciplinar de Melanoma
NCT07193966 RECRUITING
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Shenzhen Geno-Immune Medical Institute
NCT05309421 ACTIVE NOT RECRUITING
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Evaxion Biotech A/S
NCT06906822 RECRUITING
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
Grupo Español Multidisciplinar de Melanoma
NCT05893654 ENROLLING BY INVITATION
Melphalan Chemoreduction for Ocular Melanoma
Hospital das Clínicas de Ribeirão Preto
NCT04511013 RECRUITING
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT06739226 RECRUITING
Combination Immunotherapy Targeting Melanoma
Shenzhen Geno-Immune Medical Institute
NCT04283890 ACTIVE NOT RECRUITING
PHP and Immunotherapy in Metastasized UM
Leiden University Medical Center
NCT06712927 RECRUITING
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
NCT04598009 RECRUITING
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
NCT05585320 ACTIVE NOT RECRUITING
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT06359860 RECRUITING
A Study of ST-1898 for Unresectable or Metastatic Melanoma
Beijing Scitech-Mq Pharmaceuticals Limited
NCT07130032 RECRUITING
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
EuroCityClinic LLC
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT03646617 RECRUITING
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
NCT05057013 ACTIVE NOT RECRUITING
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
NCT03611868 ACTIVE NOT RECRUITING
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc.
NCT03235245 ACTIVE NOT RECRUITING
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
European Organisation for Research and Treatment of Cancer - EORTC
NCT05061134 ACTIVE NOT RECRUITING
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
AstraZeneca
NCT05308901 ACTIVE NOT RECRUITING
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
NCT04616443 RECRUITING
OH2 Injection in Combination With HX008 for Melanoma.
Binhui Biopharmaceutical Co., Ltd.
NCT05909618 RECRUITING
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Sheba Medical Center
NCT05415072 ACTIVE NOT RECRUITING
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Novartis Pharmaceuticals
NCT05315258 ACTIVE NOT RECRUITING
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
University of Oxford
NCT07063875 RECRUITING
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
St Vincent's Hospital, Sydney
NCT03467516 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
Udai Kammula
NCT05286294 ACTIVE NOT RECRUITING
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
Oslo University Hospital
NCT06560905 RECRUITING
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Royal Marsden NHS Foundation Trust
NCT04356729 ACTIVE NOT RECRUITING
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Elizabeth Buchbinder, MD
NCT07040280 NOT YET RECRUITING
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
Eastern Cooperative Oncology Group
NCT07040436 NOT YET RECRUITING
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
Oncodesign Precision Medicine
NCT05663775 RECRUITING
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
AHS Cancer Control Alberta
NCT02650986 ACTIVE NOT RECRUITING
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT05180799 ACTIVE NOT RECRUITING
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla, Inc.
NCT02743819 ACTIVE NOT RECRUITING
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
University of Chicago
NCT04140526 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4, Inc.
NCT05970497 RECRUITING
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech, Inc.
NCT06081920 RECRUITING
A Study of IBI363 in Subjects With Advanced Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
NCT06976021 NOT YET RECRUITING
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
NCT06163820 RECRUITING
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Melanoma and Skin Cancer Trials Limited
NCT06965231 RECRUITING
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Fudan University
NCT03719131 ACTIVE NOT RECRUITING
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Emory University
NCT03958383 ACTIVE NOT RECRUITING
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
NCT05275374 NOT YET RECRUITING
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Xynomic Pharmaceuticals, Inc.
NCT06797297 RECRUITING
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Innovent Biologics (Suzhou) Co. Ltd.
NCT05483400 RECRUITING
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
University Medical Center Groningen
NCT02644369 ACTIVE NOT RECRUITING
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
University Health Network, Toronto
NCT04291105 RECRUITING
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
NCT04802876 ACTIVE NOT RECRUITING
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT04722575 ACTIVE NOT RECRUITING
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Fondazione Melanoma Onlus
NCT05983237 RECRUITING
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Jun Guo
NCT05512481 RECRUITING
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
NCT05669430 RECRUITING
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT03757689 ACTIVE NOT RECRUITING
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Abramson Cancer Center at Penn Medicine
NCT06630611 RECRUITING
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Vall d'Hebron Institute of Oncology
NCT06090266 RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
NCT05877430 RECRUITING
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
NCT06281678 RECRUITING
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
NCT06727630 RECRUITING
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Zhuhai Yufan Biotechnologies Co., Ltd
NCT05361174 RECRUITING
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics, Inc.
NCT05824975 RECRUITING
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
NCT04787042 RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
NCT06240143 RECRUITING
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
The Netherlands Cancer Institute
NCT06683755 NOT YET RECRUITING
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
M.D. Anderson Cancer Center
NCT06670300 NOT YET RECRUITING
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
YongZhang
NCT06651151 RECRUITING
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Oslo University Hospital
NCT06284590 RECRUITING
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Philogen S.p.A.
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT04205227 ACTIVE NOT RECRUITING
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics, Inc
NCT05229614 RECRUITING
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
CNAO National Center of Oncological Hadrontherapy
NCT04951583 ACTIVE NOT RECRUITING
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
Centre hospitalier de l'Université de Montréal (CHUM)
NCT05013099 ACTIVE NOT RECRUITING
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb, Inc.
NCT06500091 NOT YET RECRUITING
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06470880 NOT YET RECRUITING
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
The Christie NHS Foundation Trust
NCT05060432 ACTIVE NOT RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT05955105 RECRUITING
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
NCT03842943 RECRUITING
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
University of Louisville
NCT03685890 RECRUITING
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Vastra Gotaland Region
NCT06327698 NOT YET RECRUITING
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Hunan Cancer Hospital
NCT06265025 RECRUITING
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
NCT05280314 RECRUITING
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
IO Biotech
NCT06229340 RECRUITING
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
N.N. Petrov National Medical Research Center of Oncology
NCT04729543 RECRUITING
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Erasmus Medical Center
NCT03534635 ACTIVE NOT RECRUITING
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Centre Hospitalier Universitaire Vaudois
NCT03166397 RECRUITING
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
NCT03241186 ACTIVE NOT RECRUITING
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Robert R. McWilliams, MD
NCT05539118 NOT YET RECRUITING
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Xijing Hospital
NCT01638676 RECRUITING
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
University of Louisville
NCT04331093 RECRUITING
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Di Wu
NCT04126876 RECRUITING
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
A.J.M. van den Eertwegh
NCT01676649 ACTIVE NOT RECRUITING
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
Jewish General Hospital
NCT02498756 NOT YET RECRUITING
Cytokine-induced Killer Study for Patients With Stage II Melanoma
The First People's Hospital of Changzhou
NCT04221438 TERMINATED
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
ECOG-ACRIN Cancer Research Group
NCT04527549 TERMINATED
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
ECOG-ACRIN Cancer Research Group
NCT03554083 COMPLETED
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Mayo Clinic
NCT06151847 COMPLETED
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
NCT04902040 TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT02562625 TERMINATED
Trial of Pembrolizumab and Radiotherapy in Melanoma
Royal Marsden NHS Foundation Trust
NCT05187884 COMPLETED
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
St Vincent's Hospital, Sydney
NCT01604889 TERMINATED
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
NCT04799054 TERMINATED
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Oncology Division A/S
NCT02816021 COMPLETED
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01840007 COMPLETED
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
Centre Hospitalier Universitaire de Nice
NCT03620019 COMPLETED
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
NCT02360579 COMPLETED
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Iovance Biotherapeutics, Inc.
NCT04789668 TERMINATED
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03070392 COMPLETED
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
NCT04609566 COMPLETED
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05926960 TERMINATED
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Pfizer
NCT02645149 COMPLETED
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
Melanoma Institute Australia
NCT04093323 TERMINATED
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
NCT03417739 TERMINATED
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
NCT03400332 COMPLETED
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
NCT01659151 COMPLETED
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04526730 COMPLETED
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT02517736 COMPLETED
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
University Hospital, Caen
NCT04552223 COMPLETED
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Jose Lutzky, MD
NCT05551117 TERMINATED
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
MacroGenics
NCT04913220 TERMINATED
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
NCT05419388 COMPLETED
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Hoffmann-La Roche
NCT03815058 COMPLETED
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Genentech, Inc.
NCT04157517 TERMINATED
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D LLC
NCT03873818 COMPLETED
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
NCT04526899 COMPLETED
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
NCT03405155 COMPLETED
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03993379 TERMINATED
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
NCT01319565 COMPLETED
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Cancer Institute (NCI)
NCT04688658 TERMINATED
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
John Kirkwood
NCT01950390 COMPLETED
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT05383170 COMPLETED
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
Cytovation AS
NCT04570332 COMPLETED
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Highlight Therapeutics
NCT04955743 TERMINATED
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
NCT04725331 TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
NCT02706353 TERMINATED
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT04796194 COMPLETED
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
Lytix Biopharma AS
NCT01473004 COMPLETED
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Thomas Jefferson University
NCT05169437 TERMINATED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Tempus AI
NCT01397708 COMPLETED
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Alaunos Therapeutics
NCT04700072 COMPLETED
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Merck Sharp & Dohme LLC
NCT04303169 COMPLETED
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Merck Sharp & Dohme LLC
NCT04208958 COMPLETED
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Vedanta Biosciences, Inc.
NCT05091346 COMPLETED
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
NCT04370704 COMPLETED
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Incyte Corporation
NCT04985604 TERMINATED
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT03949153 COMPLETED
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
University Hospital, Strasbourg, France
NCT06030037 WITHDRAWN
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
Diwakar Davar
NCT03712904 TERMINATED
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04577807 COMPLETED
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Istari Oncology, Inc.
NCT04305041 COMPLETED
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Merck Sharp & Dohme LLC
NCT04988841 COMPLETED
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Assistance Publique - Hôpitaux de Paris
NCT05578872 COMPLETED
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
NCT05259696 COMPLETED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Palleon Pharmaceuticals, Inc.
NCT02327078 COMPLETED
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
NCT02681549 COMPLETED
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
NCT05304546 COMPLETED
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Dr. Ronnie Shapira
NCT02553642 COMPLETED
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT05116202 COMPLETED
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Hoffmann-La Roche
NCT04720417 TERMINATED
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
NCT04493203 COMPLETED
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Yana Najjar
NCT02836548 COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
NCT06508827 WITHDRAWN
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
NCT03384836 SUSPENDED
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
NCT01378975 COMPLETED
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
NCT03645928 TERMINATED
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
NCT03325101 TERMINATED
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
NCT04698187 TERMINATED
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
NCT04830124 TERMINATED
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
Mural Oncology, Inc
NCT04068896 COMPLETED
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
NCT03898908 COMPLETED
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Grupo Español Multidisciplinar de Melanoma
NCT05542342 COMPLETED
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Grupo Español Multidisciplinar de Melanoma
NCT03618641 COMPLETED
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Diwakar Davar
NCT01864538 TERMINATED
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
NCT03472586 COMPLETED
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02875132 COMPLETED
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Chinese University of Hong Kong
NCT02902029 COMPLETED
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
University Hospital, Essen
NCT01355120 COMPLETED
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
Prof. Dr. med. Dirk Schadendorf
NCT02523313 COMPLETED
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
Prof. Dr. med. Dirk Schadendorf
NCT05669352 SUSPENDED
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
University of Florida
NCT05436990 TERMINATED
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
Yonsei University
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT02437136 COMPLETED
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
NCT04330430 COMPLETED
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
The Netherlands Cancer Institute
NCT04133948 COMPLETED
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
The Netherlands Cancer Institute
NCT05061017 COMPLETED
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Diwakar Davar
NCT05340621 COMPLETED
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
OnKure, Inc.
NCT03997474 TERMINATED
ATL001 in Patients With Metastatic or Recurrent Melanoma
Achilles Therapeutics UK Limited
NCT04417530 COMPLETED
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Aura Biosciences
NCT03167177 WITHDRAWN
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
NCT03047928 COMPLETED
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Inge Marie Svane
NCT03190174 COMPLETED
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
NCT03991130 TERMINATED
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Gregory Daniels
NCT02819843 COMPLETED
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT02936388 COMPLETED
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Charite University, Berlin, Germany
NCT02500576 COMPLETED
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT03504488 COMPLETED
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
NCT02872259 COMPLETED
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
NCT04382664 COMPLETED
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
NCT01902173 COMPLETED
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
NCT04187833 COMPLETED
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
NCT03033576 COMPLETED
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
National Cancer Institute (NCI)
NCT01884961 COMPLETED
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT01973322 COMPLETED
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT04068181 COMPLETED
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
NCT05420324 COMPLETED
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
Eucure (Beijing) Biopharma Co., Ltd
NCT05031494 COMPLETED
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
NCT05302921 COMPLETED
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
NCT04731467 COMPLETED
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Famewave Ltd.
NCT05500508 TERMINATED
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT02275416 COMPLETED
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
NCT04168528 COMPLETED
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Universitair Ziekenhuis Brussel
NCT03153085 COMPLETED
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
Takara Bio Inc.
NCT04375527 TERMINATED
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Jonsson Comprehensive Cancer Center
NCT02392871 COMPLETED
Radiotherapy & Combi in Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited
NCT05457842 TERMINATED
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
Astellas Pharma Inc
NCT01217411 TERMINATED
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
NCT04310397 TERMINATED
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
NCT04091217 COMPLETED
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Hoffmann-La Roche
NCT04401995 COMPLETED
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
Diwakar Davar
NCT03776136 COMPLETED
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Merck Sharp & Dohme LLC
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT02027935 COMPLETED
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01740557 COMPLETED
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
NCT00863330 TERMINATED
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
Wake Forest University Health Sciences
NCT03200847 COMPLETED
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
NCT03743766 COMPLETED
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
John Kirkwood
NCT03448666 WITHDRAWN
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
NCT04123470 COMPLETED
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Lokon Pharma AB
NCT05200143 TERMINATED
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
NCT02431676 COMPLETED
Survivorship Promotion In Reducing IGF-1 Trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04768881 TERMINATED
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
NCT04152863 TERMINATED
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
Merck Sharp & Dohme LLC
NCT03455764 COMPLETED
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
NCT02535078 WITHDRAWN
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
NCT04198818 TERMINATED
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Haihe Biopharma Co., Ltd.
NCT03101254 COMPLETED
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
NCT04364230 COMPLETED
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
Craig L Slingluff, Jr
NCT01894672 COMPLETED
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
NCT02981303 COMPLETED
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
HiberCell, Inc.
NCT01585194 COMPLETED
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
NCT04924413 TERMINATED
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Quanli Gao
NCT02978404 COMPLETED
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
NCT02509598 COMPLETED
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414, LLC
NCT05545969 WITHDRAWN
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
Melanoma Institute Australia
NCT03484923 COMPLETED
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis Pharmaceuticals
NCT02631447 COMPLETED
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
Fondazione Melanoma Onlus
NCT04655157 TERMINATED
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
Jason J. Luke, MD
NCT02107755 COMPLETED
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
NCT01740297 COMPLETED
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Amgen
NCT02621515 TERMINATED
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
University Medical Center Groningen
NCT02970981 COMPLETED
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NYU Langone Health
NCT03711188 COMPLETED
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
Immodulon Therapeutics Ltd
NCT05338580 WITHDRAWN
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
TJ Biopharma Co., Ltd.
NCT03625141 COMPLETED
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
NCT02978443 TERMINATED
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Georgetown University
NCT04899921 TERMINATED
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Dana-Farber Cancer Institute
NCT02678741 COMPLETED
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Elios Therapeutics, LLC
NCT03665285 COMPLETED
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT02159066 COMPLETED
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Pfizer
NCT02126579 COMPLETED
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Craig L Slingluff, Jr
NCT04455503 TERMINATED
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Evaxion Biotech A/S
NCT05060003 TERMINATED
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Washington University School of Medicine
NCT04337931 TERMINATED
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
NCT03617328 COMPLETED
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Craig L Slingluff, Jr
NCT05756556 SUSPENDED
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
NCT01320085 COMPLETED
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
NCT03511391 COMPLETED
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
University Hospital, Ghent
NCT05482074 WITHDRAWN
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
NCT00866840 COMPLETED
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Rutgers, The State University of New Jersey
NCT03850691 COMPLETED
Radiation and Combination Immunotherapy for Melanoma
Masonic Cancer Center, University of Minnesota
NCT03765229 COMPLETED
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
UNC Lineberger Comprehensive Cancer Center
NCT00979693 WITHDRAWN
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Multidisciplinary Association for Psychedelic Studies
NCT03123783 COMPLETED
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
NCT02101008 COMPLETED
Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
University of Utah
NCT02697630 COMPLETED
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
Vastra Gotaland Region
NCT02223819 COMPLETED
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
NCT04894994 TERMINATED
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
NCT04589832 TERMINATED
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Arkadiusz Z. Dudek, MD
NCT04785365 TERMINATED
Long-Term Follow-Up Study of Patients Receiving ATL001
Achilles Therapeutics UK Limited
NCT02143050 WITHDRAWN
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
NCT03089606 COMPLETED
Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
UNC Lineberger Comprehensive Cancer Center
NCT02799901 COMPLETED
Nivolumab Plus Radiotherapy in Advanced Melanoma
Centre Hospitalier Universitaire de Nice
NCT02718066 COMPLETED
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
HUYABIO International, LLC.
NCT02407171 COMPLETED
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Yale University
NCT02425306 TERMINATED
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Craig L Slingluff, Jr
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT02304458 COMPLETED
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT02743611 TERMINATED
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
NCT04059224 COMPLETED
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Universitair Ziekenhuis Brussel
NCT02403778 COMPLETED
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
NCT02831933 TERMINATED
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
Eric Bernicker, MD
NCT03207347 COMPLETED
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT05299580 WITHDRAWN
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
NCT03430947 TERMINATED
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
Technische Universität Dresden
NCT02658890 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT02515227 COMPLETED
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Craig L Slingluff, Jr
NCT02740920 TERMINATED
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
Canadian Cancer Trials Group
NCT01152788 COMPLETED
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
NCIC Clinical Trials Group
NCT05677373 WITHDRAWN
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
NCT04644315 TERMINATED
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT02748564 TERMINATED
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Rutgers, The State University of New Jersey
NCT02988817 COMPLETED
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
NCT03679767 COMPLETED
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
NCT02203604 TERMINATED
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
CINJRegulatory
NCT00700882 COMPLETED
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
NCT01559818 TERMINATED
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Immodulon Therapeutics Ltd
NCT05561491 WITHDRAWN
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax Oy
NCT01618136 COMPLETED
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Limited
NCT04987996 WITHDRAWN
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
NCT02211131 COMPLETED
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Amgen
NCT03637803 TERMINATED
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
NCT01502293 COMPLETED
Trial of pIL-12 Electroporation Malignant Melanoma
OncoSec Medical Incorporated
NCT03171064 COMPLETED
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
University Hospital Heidelberg
NCT01995344 TERMINATED
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
The Christie NHS Foundation Trust
NCT05234437 TERMINATED
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
QBiotics Group Limited
NCT04834973 TERMINATED
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
QBiotics Group Limited
NCT02054520 TERMINATED
Immunotherapy Study for Patients With Stage IV Melanoma
NewLink Genetics Corporation
NCT05496192 WITHDRAWN
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb
NCT02570308 COMPLETED
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
NCT02771626 TERMINATED
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc
NCT02983045 COMPLETED
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Nektar Therapeutics
NCT03435640 TERMINATED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Nektar Therapeutics
NCT02857569 COMPLETED
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT01993719 COMPLETED
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT02821182 COMPLETED
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
University Hospital, Ghent
NCT02731729 COMPLETED
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Parker Institute for Cancer Immunotherapy
NCT02052193 TERMINATED
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT02414750 TERMINATED
Vemurafenib Plus Cobimetinib in Metastatic Melanoma
Netherlands Working Group on Immunotherapy of Oncology
NCT05572463 WITHDRAWN
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
NCT00945269 TERMINATED
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
NCT02038348 COMPLETED
Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study
Assistance Publique Hopitaux De Marseille
NCT01807182 COMPLETED
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT02115139 COMPLETED
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma
NCT03396952 COMPLETED
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
University of California, San Francisco
NCT04172454 COMPLETED
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Akeso
NCT00679289 COMPLETED
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT03834623 COMPLETED
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03301636 TERMINATED
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
NewLink Genetics Corporation
NCT02334735 COMPLETED
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Nina Bhardwaj
NCT02089685 COMPLETED
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Merck Sharp & Dohme LLC
NCT02307500 COMPLETED
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Istituto Clinico Humanitas
NCT01835145 COMPLETED
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02404441 COMPLETED
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT02644967 COMPLETED
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
Idera Pharmaceuticals, Inc.
NCT02130466 COMPLETED
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Merck Sharp & Dohme LLC
NCT03754140 WITHDRAWN
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Melanoma Institute Australia
NCT03050060 TERMINATED
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
NCT03259425 TERMINATED
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
University of Utah
NCT03903640 TERMINATED
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Washington University School of Medicine
NCT03633110 COMPLETED
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
NCT01134250 COMPLETED
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Philogen S.p.A.
NCT01127451 COMPLETED
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
NCT03684785 TERMINATED
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT02111850 COMPLETED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Cancer Institute (NCI)
NCT02626962 COMPLETED
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT01927419 COMPLETED
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Bristol-Myers Squibb
NCT01650350 TERMINATED
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Brown University
NCT01959633 COMPLETED
Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
Fondazione Melanoma Onlus
NCT04062032 COMPLETED
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
University of Utah
NCT04066725 COMPLETED
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
University of Utah
NCT02178722 COMPLETED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
NCT01827111 COMPLETED
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT03278665 COMPLETED
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
4SC AG
NCT02083354 COMPLETED
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis Pharmaceuticals
NCT02054104 TERMINATED
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Cancer Institute (NCI)
NCT02257424 COMPLETED
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
NCT00910650 COMPLETED
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Jonsson Comprehensive Cancer Center
NCT02366195 COMPLETED
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Amgen
NCT00591734 COMPLETED
RAD001 Plus Bevacizumab in Metastatic Melanoma
SCRI Development Innovations, LLC
NCT02009397 COMPLETED
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
University of Louisville
NCT02129075 COMPLETED
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
NCT04995094 WITHDRAWN
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
HiberCell, Inc.
NCT02009384 TERMINATED
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
University of Louisville
NCT02320058 COMPLETED
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
Bristol-Myers Squibb
NCT02375984 TERMINATED
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
Saint John's Cancer Institute
NCT01335009 COMPLETED
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai Inc.
NCT02974803 TERMINATED
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Canadian Cancer Trials Group
NCT03555032 COMPLETED
TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
Royal Marsden NHS Foundation Trust
NCT01783938 COMPLETED
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
Bristol-Myers Squibb
NCT00960752 COMPLETED
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
M.D. Anderson Cancer Center
NCT02807844 COMPLETED
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT01497808 COMPLETED
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Abramson Cancer Center at Penn Medicine
NCT02521870 TERMINATED
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Dynavax Technologies Corporation
NCT04060407 WITHDRAWN
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02296112 COMPLETED
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Vanderbilt-Ingram Cancer Center
NCT02097732 TERMINATED
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
NCT03224208 TERMINATED
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
Fondazione Melanoma Onlus
NCT03724968 TERMINATED
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Elizabeth Davis
NCT04042506 WITHDRAWN
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00896480 COMPLETED
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
GlaxoSmithKline
NCT01302496 COMPLETED
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Bart Neyns
NCT01967823 COMPLETED
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Cancer Institute (NCI)
NCT04495010 WITHDRAWN
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
Bristol-Myers Squibb
NCT01037790 COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
NCT00961844 TERMINATED
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Steinar Aamdal
NCT02902042 COMPLETED
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Prof. Dr. med. Dirk Schadendorf
NCT03758729 WITHDRAWN
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
NCT02303951 TERMINATED
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
University Hospital Tuebingen
NCT03728465 TERMINATED
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
University Hospital Tuebingen
NCT01321437 COMPLETED
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
NCT02493361 COMPLETED
Trial of pIL-12/MK-3475 in Metastatic Melanoma
University of California, San Francisco
NCT02308020 COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Eli Lilly and Company
NCT02423863 COMPLETED
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Oncovir, Inc.
NCT00942162 COMPLETED
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
GlaxoSmithKline
NCT03352947 COMPLETED
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
Cambridge University Hospitals NHS Foundation Trust
NCT01781572 COMPLETED
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Pfizer
NCT03354962 TERMINATED
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
Institut Claudius Regaud
NCT01726738 COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
UNC Lineberger Comprehensive Cancer Center
NCT03241927 TERMINATED
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Nina Bhardwaj
NCT01328535 COMPLETED
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
NCT03972046 WITHDRAWN
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
NCT02709889 TERMINATED
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT02308553 COMPLETED
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
Prof. Dr. med. Dirk Schadendorf
NCT02410863 TERMINATED
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
Prof. Dr. med. Dirk Schadendorf
NCT00706238 TERMINATED
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
GlaxoSmithKline
NCT01942993 TERMINATED
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Philip Friedlander
NCT01801358 TERMINATED
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT02156804 COMPLETED
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Bristol-Myers Squibb
NCT01590082 TERMINATED
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
NCT02363283 COMPLETED
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
NCT03126461 WITHDRAWN
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
University of Texas Southwestern Medical Center
NCT01512251 COMPLETED
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
University of California, San Francisco
NCT02263898 WITHDRAWN
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
NCT03407170 TERMINATED
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
Merck Sharp & Dohme LLC
NCT01308294 TERMINATED
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
Centre Hospitalier Universitaire Vaudois
NCT02073123 COMPLETED
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
NewLink Genetics Corporation
NCT04184518 WITHDRAWN
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT03480152 TERMINATED
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT01682213 COMPLETED
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
NCT03580382 TERMINATED
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NYU Langone Health
NCT01704287 COMPLETED
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
Merck Sharp & Dohme LLC
NCT02385669 TERMINATED
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Craig L Slingluff, Jr
NCT01355562 WITHDRAWN
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
NCT02718391 TERMINATED
Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT01363206 COMPLETED
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
Lynn E. Spitler, MD
NCT02452424 TERMINATED
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
NCT01449279 COMPLETED
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Stanford University
NCT01413191 COMPLETED
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
NCT01266603 COMPLETED
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
M.D. Anderson Cancer Center
NCT02583516 COMPLETED
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT01392352 TERMINATED
HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT01970527 TERMINATED
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
University of Washington
NCT04007588 WITHDRAWN
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
NCT02587650 TERMINATED
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
NCT02537600 COMPLETED
Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
Center Eugene Marquis
NCT01065441 COMPLETED
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
Michael Har-Noy
NCT02158520 COMPLETED
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
NCT02424916 COMPLETED
Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
Nantes University Hospital
NCT02094872 COMPLETED
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Yale University
NCT01962103 COMPLETED
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
NCT01437605 TERMINATED
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
H. Lee Moffitt Cancer Center and Research Institute
NCT03300843 TERMINATED
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT01369875 TERMINATED
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Cancer Institute (NCI)
NCT01218867 TERMINATED
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT02190838 TERMINATED
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
N.N. Petrov National Medical Research Center of Oncology
NCT02014441 COMPLETED
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Amgen
NCT00670748 TERMINATED
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Cancer Institute (NCI)
NCT01196416 COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
NCT01264081 TERMINATED
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
National Cancer Institute (NCI)
NCT01136967 COMPLETED
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Eisai Inc.
NCT01883323 COMPLETED
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
NCT01551459 COMPLETED
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
The Clatterbridge Cancer Centre NHS Foundation Trust
NCT02359851 TERMINATED
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Vanderbilt-Ingram Cancer Center
NCT03007823 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
Fuda Cancer Hospital, Guangzhou
NCT02302339 TERMINATED
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
NCT01471054 TERMINATED
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Arman Mashayekhi
NCT02768207 COMPLETED
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
NCT00729807 TERMINATED
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
University of Maryland, Baltimore
NCT01107665 COMPLETED
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
University of California, Irvine
NCT03391050 TERMINATED
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Aprea Therapeutics
NCT03111901 WITHDRAWN
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
William Grosh, MD
NCT01636882 COMPLETED
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
Viralytics
NCT01227551 COMPLETED
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
Viralytics
NCT02306850 COMPLETED
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
St. Louis University
NCT02153905 TERMINATED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Cancer Institute (NCI)
NCT02039947 COMPLETED
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis Pharmaceuticals
NCT01988831 SUSPENDED
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
University Hospital, Geneva
NCT01258855 COMPLETED
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01723813 TERMINATED
Peptide Vaccinations Plus GM-CT-01 in Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01191034 TERMINATED
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01290536 COMPLETED
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Nicholas Fidelman, MD
NCT01100528 COMPLETED
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
NCT01813214 TERMINATED
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
NCT02314143 TERMINATED
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
GlaxoSmithKline
NCT01124734 COMPLETED
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Milton S. Hershey Medical Center
NCT02941744 COMPLETED
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Universitair Ziekenhuis Brussel
NCT02296996 COMPLETED
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
NCT01542255 TERMINATED
Metronomic Therapy in Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
NCT01350401 TERMINATED
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Adaptimmune
NCT02050321 TERMINATED
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
University of Arizona
NCT00929019 TERMINATED
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Radboud University Medical Center
NCT00788775 COMPLETED
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
NCT01200238 COMPLETED
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Dana-Farber Cancer Institute
NCT01666418 COMPLETED
Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel
University of Zurich
NCT00861913 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
National Cancer Institute (NCI)
NCT01814046 TERMINATED
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Cancer Institute (NCI)
NCT02763761 WITHDRAWN
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
NCT03220009 WITHDRAWN
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
NCT02272855 COMPLETED
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Takara Bio Inc.
NCT00961376 TERMINATED
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)
Providence Health & Services
NCT02155322 COMPLETED
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Merck Sharp & Dohme LLC
NCT01978236 TERMINATED
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
GlaxoSmithKline
NCT03297463 WITHDRAWN
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
NCT01673854 COMPLETED
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Bristol-Myers Squibb
NCT03326258 WITHDRAWN
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01064713 COMPLETED
Phase II Study of Tesetaxel in Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01961115 COMPLETED
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
NCT00804908 COMPLETED
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie (prior sponsor, Abbott)
NCT01323517 COMPLETED
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Memorial Sloan Kettering Cancer Center
NCT01533948 TERMINATED
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
NCT03005639 WITHDRAWN
ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Inova Health Care Services
NCT00626405 COMPLETED
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
NCT02796352 TERMINATED
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Ahmad Tarhini
NCT02812693 WITHDRAWN
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Joanne Jeter
NCT01692691 TERMINATED
Dacarbazine and Carmustine in Metastatic Melanoma
Western Regional Medical Center
NCT01543464 TERMINATED
Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
Inge Marie Svane
NCT01689974 TERMINATED
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
NYU Langone Health
NCT01984892 TERMINATED
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
Nina Bhardwaj
NCT01721603 TERMINATED
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
NCT01693068 COMPLETED
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
EMD Serono
NCT00726739 COMPLETED
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
Masonic Cancer Center, University of Minnesota
NCT00769990 WITHDRAWN
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
NCT01328106 WITHDRAWN
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
NCT01740401 TERMINATED
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Icahn School of Medicine at Mount Sinai
NCT02719015 WITHDRAWN
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01034787 COMPLETED
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
AHS Cancer Control Alberta
NCT01495988 TERMINATED
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
NCT01009515 TERMINATED
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
NCT02230306 TERMINATED
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Melissa Burgess, MD
NCT00715793 COMPLETED
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Hussein Tawbi
NCT02736123 WITHDRAWN
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
University of Pittsburgh
NCT02111863 TERMINATED
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01696045 TERMINATED
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Bristol-Myers Squibb
NCT01833767 WITHDRAWN
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Western Regional Medical Center
NCT00521001 COMPLETED
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
NCT02663258 WITHDRAWN
A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Royal Marsden NHS Foundation Trust
NCT01252251 COMPLETED
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
NCT01612221 COMPLETED
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
University of Utah
NCT01253564 COMPLETED
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
Hoffmann-La Roche
NCT01143402 COMPLETED
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
NCT00949702 COMPLETED
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
NCT00849875 TERMINATED
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
GlaxoSmithKline
NCT00925132 TERMINATED
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
NCT01701037 TERMINATED
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
NCT00397982 COMPLETED
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
NCT01395121 COMPLETED
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Institute of Cancer Research, United Kingdom
NCT01586195 TERMINATED
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Genentech, Inc.
NCT01676779 COMPLETED
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
Universitair Ziekenhuis Brussel
NCT00871481 COMPLETED
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT01530698 COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
Radboud University Medical Center
NCT00940004 COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Radboud University Medical Center
NCT01551693 TERMINATED
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
NCT01754376 TERMINATED
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
NCT02413827 TERMINATED
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Celldex Therapeutics
NCT00976573 COMPLETED
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Alliance for Clinical Trials in Oncology
NCT01026324 TERMINATED
Dinaciclib in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
NCT01781026 COMPLETED
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Yale University
NCT00601861 TERMINATED
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
Novo Nordisk A/S
NCT01705392 TERMINATED
Bevacizumab vs Dacarbazine in Metastatic Melanoma
Haukeland University Hospital
NCT02400385 WITHDRAWN
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
NCT01820364 TERMINATED
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Array BioPharma
NCT01189383 COMPLETED
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
Baylor Research Institute
NCT01619774 COMPLETED
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
NCT02661100 WITHDRAWN
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
NCT01888081 TERMINATED
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
Virogen Biotechnology Inc.
NCT01973608 TERMINATED
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
EMD Serono
NCT01029873 COMPLETED
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Altor BioScience
NCT01307618 TERMINATED
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01251978 COMPLETED
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
New England Retina Associates
NCT01133977 COMPLETED
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai Inc.
NCT02862145 WITHDRAWN
Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
Mirna Therapeutics, Inc.
NCT01777776 TERMINATED
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
NCT01092728 TERMINATED
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
M.D. Anderson Cancer Center
NCT01216696 COMPLETED
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
National Center for Tumor Diseases, Heidelberg
NCT01082887 TERMINATED
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)
Nantes University Hospital
NCT01605162 TERMINATED
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Eisai Inc.
NCT00724841 TERMINATED
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Gemin X
NCT01468818 TERMINATED
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT02062359 TERMINATED
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Cancer Institute (NCI)
NCT01120275 TERMINATED
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
NCT02094391 COMPLETED
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT01316692 TERMINATED
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Vanderbilt-Ingram Cancer Center
NCT02061007 WITHDRAWN
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT02285413 COMPLETED
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients
Radboud University Medical Center
NCT00716495 TERMINATED
Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma
AGIRx Ltd.
NCT02065466 WITHDRAWN
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
NCT00613509 TERMINATED
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi Pasteur, a Sanofi Company
NCT00936221 COMPLETED
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
NCT01990859 COMPLETED
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
Bristol-Myers Squibb
NCT01455259 COMPLETED
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
Uppsala University
NCT00738361 COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Ohio State University Comprehensive Cancer Center
NCT01200342 TERMINATED
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
M.D. Anderson Cancer Center
NCT02662725 COMPLETED
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
University Hospital, Lille
NCT02452281 WITHDRAWN
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Rabih Said
NCT01435369 COMPLETED
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Medivation, Inc.
NCT01983124 COMPLETED
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
Paola Queirolo
NCT01028222 COMPLETED
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Novartis Pharmaceuticals
NCT01099514 COMPLETED
Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
Samsung Medical Center
NCT02574260 COMPLETED
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
BioVex Limited
NCT01709162 TERMINATED
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
Bristol-Myers Squibb
NCT01236573 TERMINATED
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
National Institutes of Health Clinical Center (CC)
NCT01474551 TERMINATED
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Memorial Sloan Kettering Cancer Center
NCT01160445 TERMINATED
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Cancer Institute (NCI)
NCT00704938 TERMINATED
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
NCT00706992 TERMINATED
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Cancer Institute (NCI)
NCT00612222 TERMINATED
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
National Cancer Institute (NCI)
NCT00610311 TERMINATED
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
National Cancer Institute (NCI)
NCT00923195 COMPLETED
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01273181 TERMINATED
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Cancer Institute (NCI)
NCT00665470 COMPLETED
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
National Cancer Institute (NCI)
NCT01495572 TERMINATED
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
National Cancer Institute (NCI)
NCT01118091 COMPLETED
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
National Cancer Institute (NCI)
NCT01376713 COMPLETED
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Medical University of Vienna
NCT01764009 WITHDRAWN
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma
Valerio Therapeutics
NCT01009775 COMPLETED
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Astellas Pharma Inc
NCT00866177 COMPLETED
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
NCT01480323 COMPLETED
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
University Hospital Tuebingen
NCT00855452 COMPLETED
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
Hadassah Medical Organization
NCT01681212 COMPLETED
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Bristol-Myers Squibb
NCT01654692 COMPLETED
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Italian Network for Tumor Biotherapy
NCT00885534 COMPLETED
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
NCT00984464 COMPLETED
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Oncolytics Biotech
NCT01369888 TERMINATED
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
National Cancer Institute (NCI)
NCT01386580 COMPLETED
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
NCT01253096 COMPLETED
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Philogen S.p.A.
NCT02223884 COMPLETED
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
Yonsei University
NCT00329641 COMPLETED
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
National Cancer Institute (NCI)
NCT01531244 WITHDRAWN
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Washington University School of Medicine
NCT01519427 TERMINATED
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
National Cancer Institute (NCI)
NCT00623766 COMPLETED
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Bristol-Myers Squibb
NCT00671554 TERMINATED
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
Prisma Health-Upstate
NCT01166126 TERMINATED
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
National Cancer Institute (NCI)
NCT01266967 COMPLETED
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
GlaxoSmithKline
NCT00651157 COMPLETED
Viral Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01689870 WITHDRAWN
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT01014351 COMPLETED
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
SCRI Development Innovations, LLC
NCT01055522 TERMINATED
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Philogen S.p.A.
NCT01933061 WITHDRAWN
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene Corporation
NCT01743157 COMPLETED
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
California Pacific Medical Center Research Institute
NCT00722098 TERMINATED
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
Baylor Research Institute
NCT01216657 TERMINATED
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
Krankenhaus Nordwest
NCT01340729 WITHDRAWN
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01416844 WITHDRAWN
Study of Immune Responses in Patients With Metastatic Melanoma
Providence Health & Services
NCT01216787 WITHDRAWN
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT00627419 TERMINATED
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
NCT00835419 COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
Piramal Enterprises Limited
NCT00846833 COMPLETED
Haploidentical NK Cell Infusion in Malignant Melanoma
Seoul National University Hospital
NCT01026051 TERMINATED
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
Mannkind Corporation
NCT01048554 COMPLETED
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Mt. Sinai Medical Center, Miami
NCT01409187 WITHDRAWN
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT00658437 COMPLETED
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
Cytavis Biopharma GmbH
NCT00881049 COMPLETED
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
Peking University
NCT00623402 COMPLETED
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
University Hospital Schleswig-Holstein
NCT00651703 COMPLETED
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
NCT00609011 COMPLETED
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
Myrexis Inc.
NCT00735332 TERMINATED
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
Thallion Pharmaceuticals
NCT00794235 COMPLETED
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
NCT00963664 WITHDRAWN
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
NCT07584226 RECRUITING
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
NCT02298959 ACTIVE NOT RECRUITING
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT04855435 RECRUITING
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
NCT07581509 NOT YET RECRUITING
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Biocon Biologics UK PLC
NCT05492682 RECRUITING
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
NCT05068102 ACTIVE NOT RECRUITING
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
NCT05581004 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT05538130 RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT07562841 RECRUITING
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
West China Hospital
NCT07444606 NOT YET RECRUITING
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
M.D. Anderson Cancer Center
NCT05355701 RECRUITING
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
NCT03769155 ACTIVE NOT RECRUITING
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Emory University
NCT03025256 RECRUITING
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
NCT04620603 ACTIVE NOT RECRUITING
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
NCT03816332 ACTIVE NOT RECRUITING
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
NCT05264974 RECRUITING
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
NCT04483778 ACTIVE NOT RECRUITING
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04913285 ACTIVE NOT RECRUITING
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT07177937 RECRUITING
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
NCT06153238 ACTIVE NOT RECRUITING
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Sandoz
NCT07203391 RECRUITING
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
St Vincent's Hospital, Sydney
NCT01590069 ACTIVE NOT RECRUITING
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
NCT05571839 ACTIVE NOT RECRUITING
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06066138 RECRUITING
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Cancer Institute (NCI)
NCT06326411 RECRUITING
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics, Inc
NCT06150664 RECRUITING
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT05470283 ACTIVE NOT RECRUITING
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT06545682 RECRUITING
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
NCT06660420 RECRUITING
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
NCT05039801 RECRUITING
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT04897321 RECRUITING
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT07518043 NOT YET RECRUITING
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT01955460 ACTIVE NOT RECRUITING
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT01480154 ACTIVE NOT RECRUITING
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
NCT01366144 ACTIVE NOT RECRUITING
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT01364051 ACTIVE NOT RECRUITING
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
NCT01303341 ACTIVE NOT RECRUITING
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
National Cancer Institute (NCI)
NCT05858736 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
OncoC4, Inc.
NCT04044859 ACTIVE NOT RECRUITING
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM CT, LLC
NCT06566092 ACTIVE NOT RECRUITING
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics, Inc.
NCT05496686 ACTIVE NOT RECRUITING
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Modulation Therapeutics, Inc.
NCT07476326 NOT YET RECRUITING
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Biologics UK PLC
NCT07501117 NOT YET RECRUITING
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Inge Marie Svane
NCT04328844 ACTIVE NOT RECRUITING
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
NCT04835805 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
NCT04930783 ACTIVE NOT RECRUITING
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
NCT04514484 ACTIVE NOT RECRUITING
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT04038619 RECRUITING
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04007744 ACTIVE NOT RECRUITING
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT04119024 RECRUITING
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT07076550 RECRUITING
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
NCT07475572 NOT YET RECRUITING
A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Alvotech Swiss AG
NCT05098210 RECRUITING
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
NCT03819296 RECRUITING
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
NCT04697576 RECRUITING
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Carlo Contreras
NCT04020809 ACTIVE NOT RECRUITING
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
NCT06961786 ACTIVE NOT RECRUITING
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
TILT Biotherapeutics Ltd.
NCT02721459 ACTIVE NOT RECRUITING
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05869539 ACTIVE NOT RECRUITING
ACT-TIL and ANV419 for Advanced Melanoma.
University Hospital, Basel, Switzerland
NCT07027488 RECRUITING
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Yale University
NCT05176470 ACTIVE NOT RECRUITING
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Richard Wu
NCT07414979 NOT YET RECRUITING
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
M.D. Anderson Cancer Center
NCT07160335 RECRUITING
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT04903119 RECRUITING
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Rina Plattner
NCT06014086 ACTIVE NOT RECRUITING
Intratumoral PH-762 for Cutaneous Carcinoma
Phio Pharmaceuticals Inc.
NCT05607095 RECRUITING
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT07376707 RECRUITING
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
NCT02432963 ACTIVE NOT RECRUITING
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT03891953 ACTIVE NOT RECRUITING
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03021460 ACTIVE NOT RECRUITING
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Mayo Clinic
NCT05902520 ACTIVE NOT RECRUITING
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx, Inc.
NCT04616248 ACTIVE NOT RECRUITING
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT05544929 ACTIVE NOT RECRUITING
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT03929029 ACTIVE NOT RECRUITING
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
NCT05075993 ACTIVE NOT RECRUITING
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT06022029 RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.
NCT03161431 ACTIVE NOT RECRUITING
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Syntrix Biosystems, Inc.
NCT05859074 RECRUITING
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT02869217 ACTIVE NOT RECRUITING
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
NCT07260591 RECRUITING
VSV-02 Compassionate Use in Advanced Solid Tumors
The First Affiliated Hospital of Xinxiang Medical College
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT07252661 NOT YET RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
NCT07106827 RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
NCT06332755 RECRUITING
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT07086105 RECRUITING
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
Adze Biotechnology Australia Pty Ltd
NCT05238883 ACTIVE NOT RECRUITING
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069 ACTIVE NOT RECRUITING
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT06897735 NOT YET RECRUITING
Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
Petrov, Andrey
NCT04875728 ACTIVE NOT RECRUITING
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
M.D. Anderson Cancer Center
NCT05973487 ACTIVE NOT RECRUITING
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics, Inc.
NCT04495257 ACTIVE NOT RECRUITING
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
NCT03589339 ACTIVE NOT RECRUITING
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
NCT06540391 ACTIVE NOT RECRUITING
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
Microbiotica Ltd
NCT06805825 RECRUITING
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
NCT06636435 RECRUITING
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Chiome Bioscience Inc.
NCT07183852 NOT YET RECRUITING
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
Vastra Gotaland Region
NCT05629546 RECRUITING
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Washington University School of Medicine
NCT05640193 ACTIVE NOT RECRUITING
A Study of LN-144 in People With Metastatic Melanoma to the Brain
Memorial Sloan Kettering Cancer Center
NCT03454035 RECRUITING
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
NCT05653882 ACTIVE NOT RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics, Inc.
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT06551064 ACTIVE NOT RECRUITING
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Formycon AG
NCT06398418 RECRUITING
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics LLC
NCT06942143 RECRUITING
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT05077137 RECRUITING
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Duke University
NCT06204991 RECRUITING
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Inge Marie Svane
NCT06941818 ENROLLING BY INVITATION
HS-IT101 Injection in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
NCT05222932 ACTIVE NOT RECRUITING
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
TILT Biotherapeutics Ltd.
NCT07107178 NOT YET RECRUITING
A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Biotroy Therapeutics
NCT03872947 ACTIVE NOT RECRUITING
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT04572451 RECRUITING
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT03635632 ACTIVE NOT RECRUITING
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
NCT06377111 RECRUITING
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
NCT03336606 ACTIVE NOT RECRUITING
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT06112808 ACTIVE NOT RECRUITING
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Biocad
NCT06596915 RECRUITING
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
NCT03311308 RECRUITING
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
Yana Najjar
NCT05967533 RECRUITING
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT06889766 RECRUITING
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Centre Hospitalier Universitaire Vaudois
NCT03772899 ACTIVE NOT RECRUITING
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT06783270 RECRUITING
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Inge Marie Svane
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT05130255 RECRUITING
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
NCT05867303 ACTIVE NOT RECRUITING
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
NCT06424626 NOT YET RECRUITING
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
Peking University Cancer Hospital & Institute
NCT05354102 ACTIVE NOT RECRUITING
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
Biomica Ltd.
NCT04282044 RECRUITING
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT05746897 RECRUITING
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
NCT05620290 RECRUITING
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
Sunnybrook Health Sciences Centre
NCT05903937 NOT YET RECRUITING
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Vastra Gotaland Region
NCT03743298 RECRUITING
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
Aivita Biomedical, Inc.
NCT05366478 RECRUITING
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
Suzhou BlueHorse Therapeutics Co., Ltd.
NCT01586403 ACTIVE NOT RECRUITING
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
Loyola University
NCT02870244 RECRUITING
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Loyola University
NCT07600476 RECRUITING
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Kupando GmbH
NCT04640545 COMPLETED
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
NCT02437227 COMPLETED
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Royal Marsden NHS Foundation Trust
NCT06870487 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT03552718 COMPLETED
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
NCT05341349 TERMINATED
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT06974734 TERMINATED
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Pfizer
NCT03881488 COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
NCT03114319 TERMINATED
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT03236935 COMPLETED
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT02668770 TERMINATED
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT05628883 COMPLETED
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05148325 COMPLETED
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
Bio-Thera Solutions
NCT03293784 COMPLETED
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
Institut Claudius Regaud
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT06580938 TERMINATED
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
NCT03420963 TERMINATED
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT06799533 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Pfizer
NCT02410733 COMPLETED
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
BioNTech SE
NCT02858869 COMPLETED
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
NCT06287463 TERMINATED
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Deciphera Pharmaceuticals, LLC
NCT04335890 COMPLETED
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
Hasumi International Research Foundation
NCT03501368 COMPLETED
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01625351 COMPLETED
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
NCT02989064 COMPLETED
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
NCT03865212 TERMINATED
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Mayo Clinic
NCT04109456 COMPLETED
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
NCT01970358 COMPLETED
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Patrick Ott, MD, PhD
NCT06626256 WITHDRAWN
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
NCT05393713 TERMINATED
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Mayo Clinic
NCT02639026 COMPLETED
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
NCT05668585 COMPLETED
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
NCT06052852 TERMINATED
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
NCT04543188 TERMINATED
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
NCT05229601 TERMINATED
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT04935229 TERMINATED
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
TriSalus Life Sciences, Inc.
NCT05293496 COMPLETED
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
NCT04812470 COMPLETED
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
Vastra Gotaland Region
NCT06285097 TERMINATED
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
NCT04772989 COMPLETED
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03708328 COMPLETED
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05388877 TERMINATED
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
NCT05004025 COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
HonorHealth Research Institute
NCT07121829 TERMINATED
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT01863108 COMPLETED
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma
University Hospital, Grenoble
NCT02475213 COMPLETED
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
NCT04217473 COMPLETED
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma
TILT Biotherapeutics Ltd.
NCT05717140 WITHDRAWN
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
NCT05585034 COMPLETED
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NCT01239134 COMPLETED
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Leap Therapeutics, Inc.
NCT05303493 COMPLETED
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma
Centre hospitalier de l'Université de Montréal (CHUM)
NCT04904185 TERMINATED
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Inge Marie Svane
NCT06299163 TERMINATED
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
NCT04116320 TERMINATED
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
Craig L Slingluff, Jr
NCT02680184 COMPLETED
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Regeneron Pharmaceuticals
NCT03289962 COMPLETED
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
NCT03991741 TERMINATED
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Gregory Daniels
NCT05573035 TERMINATED
A Study to Investigate LYL845 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
NCT00683670 COMPLETED
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
University of Pennsylvania
NCT05432193 TERMINATED
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
NCT01351103 COMPLETED
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis Pharmaceuticals
NCT02836795 COMPLETED
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT06190249 WITHDRAWN
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
James Isaacs, MD
NCT02419495 TERMINATED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT02029729 COMPLETED
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Biogen
NCT04152018 TERMINATED
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
NCT01703507 COMPLETED
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03922880 COMPLETED
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
NCT02318771 COMPLETED
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04301011 TERMINATED
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Turnstone Biologics, Corp.
NCT02974725 TERMINATED
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Novartis Pharmaceuticals
NCT04625205 TERMINATED
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
BioNTech US Inc.
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT04463368 COMPLETED
Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
Vastra Gotaland Region
NCT05695898 TERMINATED
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
University of California, San Francisco
NCT03195699 COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT05576077 TERMINATED
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Turnstone Biologics, Corp.
NCT05909995 TERMINATED
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
NCT03475134 COMPLETED
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Centre Hospitalier Universitaire Vaudois
NCT03665597 COMPLETED
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Merck Sharp & Dohme LLC
NCT01638533 COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
NCT03026517 COMPLETED
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
NCT05653661 WITHDRAWN
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
NCT03092453 COMPLETED
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
NCT04967196 TERMINATED
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Mayo Clinic
NCT03950635 TERMINATED
Dietary Intervention in Patients with a History of Melanoma
M.D. Anderson Cancer Center
NCT02009449 COMPLETED
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT06448364 TERMINATED
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Pfizer
NCT05169957 COMPLETED
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
University of Michigan Rogel Cancer Center
NCT04504669 COMPLETED
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
NCT06034860 TERMINATED
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
NCT04096638 COMPLETED
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
invoX Pharma Limited
NCT03809624 TERMINATED
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Inhibrx Biosciences, Inc
NCT02097225 TERMINATED
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03875079 COMPLETED
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
Hoffmann-La Roche
NCT03864042 COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
NCT02791334 COMPLETED
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT05810740 COMPLETED
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
NCT03538314 COMPLETED
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Ultimovacs ASA
NCT02595866 COMPLETED
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
NCT02020707 COMPLETED
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
NCT03978611 TERMINATED
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Bristol-Myers Squibb
NCT03752398 COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Xencor, Inc.
NCT03502330 COMPLETED
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
NCT05578820 COMPLETED
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
NCT05003622 COMPLETED
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
Pierre Fabre Medicament
NCT03621982 TERMINATED
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT03817125 COMPLETED
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Parker Institute for Cancer Immunotherapy
NCT02821000 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Merck Sharp & Dohme LLC
NCT03629756 COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT02107963 COMPLETED
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Cancer Institute (NCI)
NCT01621490 COMPLETED
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Bristol-Myers Squibb
NCT05061537 TERMINATED
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
NCT04165967 COMPLETED
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
University Hospital, Basel, Switzerland
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03932253 SUSPENDED
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT03727789 TERMINATED
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
Roswell Park Cancer Institute
NCT03590054 COMPLETED
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT01738139 COMPLETED
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
NCT02723006 TERMINATED
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Millennium Pharmaceuticals, Inc.
NCT04653038 TERMINATED
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
Zai Lab (Shanghai) Co., Ltd.
NCT04244552 TERMINATED
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
NCT01709435 COMPLETED
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02482168 COMPLETED
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
NCT03980314 COMPLETED
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
Bristol-Myers Squibb
NCT04809805 TERMINATED
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer
Bayer
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT02729298 COMPLETED
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT04904120 COMPLETED
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Perspective Therapeutics
NCT03272464 TERMINATED
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
NCT02273219 COMPLETED
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Columbia University
NCT03064763 COMPLETED
Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Amgen
NCT01176474 COMPLETED
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04452214 COMPLETED
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT03399448 TERMINATED
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
University of Pennsylvania
NCT04348916 TERMINATED
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
NCT02575404 COMPLETED
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
NCT00790010 COMPLETED
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
NCT03408587 COMPLETED
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
Viralytics
NCT02141542 COMPLETED
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
F. Stephen Hodi, MD
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT01191775 COMPLETED
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
NCT01164891 COMPLETED
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
Hoffmann-La Roche
NCT02890368 TERMINATED
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
NCT02120222 COMPLETED
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
Kari Kendra
NCT03878719 TERMINATED
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Pfizer
NCT03849469 COMPLETED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Xencor, Inc.
NCT04837677 COMPLETED
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
NCT03689192 COMPLETED
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
NCT02738489 COMPLETED
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma
Jiangsu HengRui Medicine Co., Ltd.
NCT04759846 WITHDRAWN
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
NCT02032810 COMPLETED
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01657591 COMPLETED
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01176461 COMPLETED
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT02565992 COMPLETED
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Viralytics
NCT02307149 COMPLETED
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
Viralytics
NCT01456104 COMPLETED
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
Memorial Sloan Kettering Cancer Center
NCT02607813 TERMINATED
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis Pharmaceuticals
NCT04762225 TERMINATED
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
Repertoire Immune Medicines
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT02857270 COMPLETED
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
NCT02659540 COMPLETED
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
Ludwig Institute for Cancer Research
NCT01810016 TERMINATED
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT01838200 TERMINATED
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT04551352 COMPLETED
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
NCT02601378 TERMINATED
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Novartis Pharmaceuticals
NCT03084640 COMPLETED
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
Regeneron Pharmaceuticals
NCT01744171 TERMINATED
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
Roswell Park Cancer Institute
NCT04596033 TERMINATED
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
NCT02434354 COMPLETED
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Abramson Cancer Center at Penn Medicine
NCT03332589 TERMINATED
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Spirita Oncology, LLC
NCT01213732 COMPLETED
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
Philogen S.p.A.
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT01904123 COMPLETED
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT01940809 TERMINATED
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02381314 COMPLETED
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
MacroGenics
NCT01918930 TERMINATED
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
MacroGenics
NCT02482532 COMPLETED
Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Gary Doolittle
NCT02818023 TERMINATED
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Yana Najjar
NCT02573259 COMPLETED
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Pfizer
NCT00730639 COMPLETED
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
Bristol-Myers Squibb
NCT02716948 COMPLETED
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03178851 COMPLETED
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Hoffmann-La Roche
NCT03652077 COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03003676 COMPLETED
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Targovax Oy
NCT02983006 COMPLETED
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT04955262 WITHDRAWN
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Nektar Therapeutics
NCT02112032 COMPLETED
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Hassane M. Zarour, MD
NCT03773744 WITHDRAWN
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Turnstone Biologics, Corp.
NCT03425461 TERMINATED
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Jonsson Comprehensive Cancer Center
NCT02110355 COMPLETED
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
NCT01024231 COMPLETED
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Bristol-Myers Squibb
NCT02897765 COMPLETED
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech US Inc.
NCT02339324 COMPLETED
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Yana Najjar
NCT01430416 COMPLETED
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Novartis Pharmaceuticals
NCT01149343 COMPLETED
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
GlaxoSmithKline
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT02012231 TERMINATED
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
NCT02771340 COMPLETED
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Iconic Therapeutics, Inc.
NCT02029690 TERMINATED
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Polaris Group
NCT03597282 TERMINATED
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
BioNTech US Inc.
NCT02346955 TERMINATED
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Famewave Ltd.
NCT03158935 COMPLETED
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
University Health Network, Toronto
NCT01425008 COMPLETED
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Millennium Pharmaceuticals, Inc.
NCT01005472 COMPLETED
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Jonsson Comprehensive Cancer Center
NCT01656642 COMPLETED
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
NCT01211262 COMPLETED
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Immunocore Ltd
NCT02823405 COMPLETED
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
X4 Pharmaceuticals
NCT02387125 TERMINATED
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT01897116 COMPLETED
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
NCT01826448 TERMINATED
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Daiichi Sankyo
NCT00739609 TERMINATED
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NewLink Genetics Corporation
NCT03565406 TERMINATED
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT02516527 COMPLETED
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
Bristol-Myers Squibb
NCT01916135 COMPLETED
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT02285101 COMPLETED
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
Bio-Cancer Treatment International Limited
NCT03002376 COMPLETED
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Regeneron Pharmaceuticals
NCT01103635 COMPLETED
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
NCT02180061 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Merck Sharp & Dohme LLC
NCT02968680 TERMINATED
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
University of Southern California
NCT01307267 COMPLETED
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01313429 TERMINATED
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Cancer Institute (NCI)
NCT04274816 COMPLETED
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
A.J.M. van den Eertwegh
NCT02608034 COMPLETED
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Genentech, Inc.
NCT03052205 COMPLETED
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Idera Pharmaceuticals, Inc.
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT03159117 COMPLETED
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
NCT02014116 TERMINATED
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
Eli Lilly and Company
NCT02676869 COMPLETED
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Immutep Australia Pty. Ltd.
NCT01336985 TERMINATED
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
NCT01585415 TERMINATED
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Cancer Institute (NCI)
NCT02586987 COMPLETED
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
NCT01021059 COMPLETED
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
NCT01213472 COMPLETED
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
GlaxoSmithKline
NCT02387307 COMPLETED
A Study of rSIFN-co in Subjects With Advanced Solid Tumors
Sichuan Huiyang Life Science and Technology Corporation
NCT02711345 TERMINATED
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
Novartis Pharmaceuticals
NCT02045368 COMPLETED
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
IGF Oncology, LLC
NCT01271803 COMPLETED
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
NCT01639911 COMPLETED
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
NCT02891616 TERMINATED
18F-FLT PET Imaging in Patients With Advanced Melanoma
Washington University School of Medicine
NCT01996202 COMPLETED
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Duke University
NCT00636558 COMPLETED
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Viralytics
NCT01137006 COMPLETED
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Eli Lilly and Company
NCT02300935 WITHDRAWN
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
NCT01910181 COMPLETED
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Hoffmann-La Roche
NCT01017185 COMPLETED
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Takara Bio Inc.
NCT01603212 COMPLETED
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
NCT02027961 COMPLETED
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
NCT03472027 COMPLETED
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
Biocad
NCT02117362 COMPLETED
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Providence Health & Services
NCT02122861 COMPLETED
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02068079 WITHDRAWN
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Duke University
NCT01457131 TERMINATED
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
National Cancer Institute (NCI)
NCT02327390 TERMINATED
Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma
Case Comprehensive Cancer Center
NCT00791271 TERMINATED
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
M.D. Anderson Cancer Center
NCT02115243 COMPLETED
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
Duke University
NCT01986426 COMPLETED
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
NCT01876641 TERMINATED
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Mohammed M Milhem
NCT02447939 WITHDRAWN
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
NCT02650635 TERMINATED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
NCT01608594 COMPLETED
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
Diwakar Davar
NCT01636960 TERMINATED
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
Merck Sharp & Dohme LLC
NCT01341496 TERMINATED
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
National Cancer Institute (NCI)
NCT02839694 WITHDRAWN
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Cancer Institute (NCI)
NCT02166255 COMPLETED
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT02696356 COMPLETED
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
BrightPath Biotherapeutics
NCT02915666 WITHDRAWN
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
NCT02138292 COMPLETED
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
University of Texas Southwestern Medical Center
NCT02543645 TERMINATED
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
NCT01893099 COMPLETED
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Centre Hospitalier Universitaire Vaudois
NCT01943422 COMPLETED
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
John Kirkwood
NCT02613325 COMPLETED
fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth
Washington University School of Medicine
NCT01460134 COMPLETED
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Celldex Therapeutics
NCT01711684 COMPLETED
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
Rockefeller University
NCT00667082 COMPLETED
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
NCT02441465 COMPLETED
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
NCT01727076 COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
National Cancer Institute (NCI)
NCT01622933 COMPLETED
Multiple Antigen-Engineered DC Vaccine for Melanoma
Lisa H. Butterfield, Ph.D.
NCT01864759 COMPLETED
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
Institut Català d'Oncologia
NCT02935790 COMPLETED
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Celgene
NCT02015416 COMPLETED
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT00743496 COMPLETED
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
St. Jude Children's Research Hospital
NCT01001299 COMPLETED
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
Hoffmann-La Roche
NCT02489266 WITHDRAWN
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
National Cancer Institute (NCI)
NCT02210104 WITHDRAWN
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
M.D. Anderson Cancer Center
NCT01067066 TERMINATED
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
M.D. Anderson Cancer Center
NCT00471471 COMPLETED
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ahmad Tarhini
NCT00631072 COMPLETED
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Beth Israel Deaconess Medical Center
NCT01409174 TERMINATED
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT00658892 COMPLETED
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
NCT01496807 COMPLETED
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01760499 COMPLETED
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
H. Lee Moffitt Cancer Center and Research Institute
NCT01611675 TERMINATED
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Massachusetts General Hospital
NCT01065467 COMPLETED
Panobinostat (LBH589) in Patients With Metastatic Melanoma
Dana-Farber Cancer Institute
NCT01844674 COMPLETED
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
Hoffmann-La Roche
NCT01390818 COMPLETED
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
EMD Serono
NCT00861406 COMPLETED
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
M.D. Anderson Cancer Center
NCT02200562 TERMINATED
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
University of Utah
NCT01121718 COMPLETED
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Dana-Farber Cancer Institute
NCT01984255 TERMINATED
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
University of Texas Southwestern Medical Center
NCT01264731 COMPLETED
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
University of Virginia
NCT00705640 COMPLETED
Vaccine Therapy in Treating Patients With Advanced Melanoma
Craig L Slingluff, Jr
NCT00977145 TERMINATED
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Craig L Slingluff, Jr
NCT01765543 COMPLETED
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
NCT01690377 COMPLETED
Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients
Radboud University Medical Center
NCT00765921 COMPLETED
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Massachusetts Eye and Ear Infirmary
NCT01950195 TERMINATED
SRS (Stereotactic Radiosurgery) Plus Ipilimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01765556 WITHDRAWN
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
NCT01264380 COMPLETED
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
NCT01849666 COMPLETED
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
NCT01851824 COMPLETED
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
NCT01522664 COMPLETED
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Genentech, Inc.
NCT01039844 TERMINATED
Study of Weekly LOC-paclitaxel Injection for Melanoma
M.D. Anderson Cancer Center
NCT01519323 TERMINATED
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Hoffmann-La Roche
NCT01522820 COMPLETED
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
NCT01829971 TERMINATED
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
NCT01935453 COMPLETED
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
OrienGene Biotechnology Ltd.
NCT01585350 COMPLETED
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
Craig L Slingluff, Jr
NCT01846143 COMPLETED
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
Craig L Slingluff, Jr
NCT01557114 TERMINATED
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT01078961 COMPLETED
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Massachusetts General Hospital
NCT01435499 COMPLETED
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01563614 TERMINATED
A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain
University Hospital, Bonn
NCT02357732 WITHDRAWN
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
NCT00625456 COMPLETED
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Jennerex Biotherapeutics
NCT00833807 COMPLETED
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
M.D. Anderson Cancer Center
NCT01295931 COMPLETED
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
M.D. Anderson Cancer Center
NCT01783431 TERMINATED
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
Medical University of South Carolina
NCT01008527 COMPLETED
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
NCT01765569 COMPLETED
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
NCT01045915 TERMINATED
Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma
Valerio Therapeutics
NCT01107418 COMPLETED
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
NCT00978913 COMPLETED
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
Inge Marie Svane
NCT01672450 COMPLETED
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
University of Utah
NCT01216436 TERMINATED
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Duke University
NCT00753415 COMPLETED
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
NCT00661336 WITHDRAWN
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
Duke University
NCT01127594 COMPLETED
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Douglas Tyler
NCT01400451 TERMINATED
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Bristol-Myers Squibb
NCT01131234 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02077114 COMPLETED
Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma
Herlev Hospital
NCT01835184 TERMINATED
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT01841463 SUSPENDED
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Piramal Enterprises Limited
NCT01489059 COMPLETED
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Bristol-Myers Squibb
NCT00710515 COMPLETED
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
AstraZeneca
NCT01212276 TERMINATED
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Morphotek
NCT00920907 COMPLETED
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma
Bristol-Myers Squibb
NCT01066390 COMPLETED
A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Bart Neyns
NCT01339663 COMPLETED
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT00672542 COMPLETED
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Scott Pruitt
NCT00796991 COMPLETED
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
Bristol-Myers Squibb
NCT00815607 COMPLETED
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
Alaunos Therapeutics
NCT01011530 COMPLETED
Dose Escalation Study of MLN4924 in Adults With Melanoma
Millennium Pharmaceuticals, Inc.
NCT00948467 COMPLETED
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
Millennium Pharmaceuticals, Inc.
NCT01245556 COMPLETED
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
Bristol-Myers Squibb
NCT00937482 TERMINATED
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00970996 COMPLETED
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
M.D. Anderson Cancer Center
NCT01308762 COMPLETED
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
Immodulon Therapeutics Ltd
NCT00798629 COMPLETED
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
H. Lee Moffitt Cancer Center and Research Institute
NCT01294735 COMPLETED
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Merck Sharp & Dohme LLC
NCT00750399 COMPLETED
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
The New York Eye Cancer Center
NCT01052142 COMPLETED
Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
Lipotek Pty Ltd
NCT01106235 TERMINATED
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT01455103 WITHDRAWN
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
Bristol-Myers Squibb
NCT00803374 WITHDRAWN
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Bristol-Myers Squibb
NCT00747825 TERMINATED
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
Molecular Insight Pharmaceuticals, Inc.
NCT00734188 COMPLETED
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Pain Therapeutics
NCT00688090 COMPLETED
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
Mannkind Corporation
NCT00625768 COMPLETED
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Antisoma Research
NCT07574047 NOT YET RECRUITING
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Swiss Cancer Institute
NCT07405086 RECRUITING
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT07504796 RECRUITING
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
NCT07459543 NOT YET RECRUITING
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
NCT07004335 NOT YET RECRUITING
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
Hebei Medical University Fourth Hospital
NCT06785974 NOT YET RECRUITING
Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
Erasmus Medical Center
NCT02068196 ACTIVE NOT RECRUITING
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
Oslo University Hospital
NCT07092410 WITHDRAWN
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
SRH Wald-Klinikum Gera GmbH
NCT03673332 TERMINATED
Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
Institut Paoli-Calmettes
NCT02626065 COMPLETED
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
Hospices Civils de Lyon
NCT03715205 COMPLETED
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Merck Sharp & Dohme LLC
NCT01794793 COMPLETED
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
NCT01735955 COMPLETED
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis Pharmaceuticals
NCT04074460 COMPLETED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
Peter MacCallum Cancer Centre, Australia
NCT00414765 COMPLETED
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Novartis Pharmaceuticals
NCT01683188 TERMINATED
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Clinigen, Inc.
NCT02451488 COMPLETED
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
NCT01898585 COMPLETED
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Hoffmann-La Roche
Full Melanoma Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only